This is a working overview of Toll-like receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
===== Type 2A ===== VWD Type 2A results from a loss-of-function mutation in von Willebrand factor (VWF), leading to reduced binding of VWF with Platelet GP1b receptors. This disorder follows an autosomal dominant inheritance pattern with only occasional cases following autosomal recessive pattern. It accounts for 10-15% of all VWD cases. It manifests with moderate to moderately severe bleeding. Diagnostic features of VWD Type 2A include greater reduction in VWF activity (measured by a functional assay) compared to VWF antigen (quantity). This results in a decreased VWF Activity to Antigen ratio. Additionally, high molecular weight multimers are either absent or very low on electrophoresis due to impaired multimer assembly or increased susceptibility to ADAMTS13 (a protease that cleaves VWF). Factor VIII activity can be normal or low. Ristocetin-induced platelet aggregation (RIPA) is typically low.
Nobelium (102No) is a synthetic element, and thus a standard atomic weight cannot be given. Like all synthetic elements, it has no stable isotopes. The first isotope to be synthesized (and correctly identified) was 254No in 1966. There are fourteen known radioisotopes, which are 248No to 260No and 262No, and many isomers. The longest-lived isotope is 259No with a half-life of 58 minutes. The longest-lived isomer is 251m1No with a half-life of 1.02 seconds.
== Hybridization == Many species that share the same genus have been known to interbreed and create hybrids. Many species of crotalid rattlesnakes have been documented hybridizing in their natural habitats and in captivity. In southwestern New Mexico the Mojave rattlesnake is known to hybridize with the Prairie rattlesnake. These hybrids have been shown to have an overall lower body condition than either parent species. Experiments with hybrids between C. viridis and C. scutulatus have shown no advantage when it comes to hunting and the metrics are about the same across all species. The hybridization of rattlesnake species can also lead to a change in the overall venom toxicity and composition. This change can lead to a difficulty in treating bites. Rattlesnakes offer the best example for venom differences across the genus with many different species possessing different venom types. It is believed that hybridization is one of the leading causes for this variation in venom types and envenoming strategies.
Lactic acid fermentation is also used in the production of sauerkraut. The main type of bacteria used in the production of sauerkraut is of the genus Leuconostoc. As in yogurt, when the acidity rises due to lactic acid-fermenting organisms, many other pathogenic microorganisms are killed. The bacteria produce lactic acid, as well as simple alcohols and other hydrocarbons. These may then combine to form esters, contributing to the unique flavor of sauerkraut.
Sources: en.wikipedia.org
In January 2023, Whirlpool and Arçelik A.Ş. agreed to start a new joint venture, Beko Europe B.V., which was to take over Whirlpool's appliance business in Europe, Middle East, and Africa. In August 2023, the Competition and Markets Authority started a merger inquiry, deciding in October 2023 that an in-depth investigation into this joint venture would be needed to ensure that it would not reduce competition in the UK market. This process concluded in March 2024, allowing the joint venture to go through. Arçelik owns 75% of Beko Europe while Whirlpool owns 25%, and the new joint venture now operates former Whirlpool brands such as Hotpoint and Indesit. In February 2024, Whirlpool announced the sale of a 24% stake in its Indian subsidiary for $428 million, retaining a 51% ownership. Supermicro will replace Whirlpool in the S&P 500 starting at market open March 18, 2024. It was possible after the sequential decline in Whirlpool's market cap, from 14.2B in the end of 2021 to less than 6B in March 2024. In 2024, Whirlpool finalized major aspects of its portfolio transformation to reshape itself into a higher-growth, higher-margin business focused primarily on the Americas. As part of this geographic consolidation, the company successfully reduced its ownership stake in Whirlpool of India from a majority position to a minority holding of approximately 40%. Throughout 2025, Whirlpool faced a challenging macroeconomic environment characterized by depressed U.S. housing market activity and weakened discretionary consumer demand due to home affordability issues.
A trial with the primary objective of showing that the response to two or more treatments differs by an amount which is clinically unimportant. This is usually demonstrated by showing that the true treatment difference is likely to lie between a lower and an upper equivalence margin of clinically acceptable differences. (ICH E9) Essential Documents
In 2020, world production of soybeans was over 353 million tonnes, led by Brazil and the United States combined with 66% of the total (table). Production has dramatically increased across the globe since the 1960s, but particularly in South America after a cultivar that grew well in low latitudes was developed in the 1980s. The rapid growth of the industry has been primarily fueled by large increases in worldwide demand for meat products, particularly in developing countries like China, which alone accounts for more than 60% of imports. Soy is a staple crop; global soy production accounts for four times more legume production than all other legumes combined.
bond Any persistent attraction between atoms, ions, or molecules that enables the formation of chemical compounds. Bonds are created as a result of a wide variety of electrochemical forces, whose strengths can vary considerably; they are broken when these forces are overcome by other forces. The types, strengths, and quantities of bonds holding together chemical substances dictate the structure and bulk properties of matter.
=== British Empire Medal (BEM) === Alwyn Enoe. For services to Entrepreneurships. The Reverend Dave King, Presiding Bishop, River Sallee Pentecostal Church/Temple of Deliverance, Grenada District. For services to Religious Affairs and Social Work
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.